Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB2102 in Extensive Stage Small Cell Lung Cancer or Large Cell Neuroendocrine Lung Cancer
NCT05680922Phase 1Active, not recruiting
- Sponsor
- Legend Biotech Corporation
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LB2102 in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma of the lung (LCNEC), sponsored by Legend Biotech Corporation. Primary endpoints: Safety and Tolerability (RDE) at 28 days and Safety and Tolerability (RP2D) at 90 days. Started Jul 2023; status: active, not recruiting.
02
Drugs
LB2102
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma of the lung (LCNEC)
Beyond the preview
Go deeper on NCT05680922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05680922.